Checking In on Cancer Checkpoint Inhibitors

Earlier this year, former U.S. President Jimmy Carter announced that he was undergoing treatment for advanced melanoma that included the immunotherapy drug pembrolizumab (Keytruda®)—part of a class of drugs known as checkpoint inhibitors. He recently reported that his most recent MRI scan did not reveal any signs of the original cancer or any new tumors.

In this interview, James Gulley, M.D., Ph.D., head of the Immunotherapy Section in the Genitourinary Malignancy Branch of NCI's Center for Cancer Research and director of the Center's Medical Oncology Service, discusses checkpoint inhibitors, their impact on patient care, and future directions for these therapies.

from Cancer via ola Kala on Inoreader http://ift.tt/1OFeOu9
via IFTTT